Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

WAKAYAMA MEDICAL UNIVERSITY

Home Clinical Trial Sponsors and OrganizationsWAKAYAMA MEDICAL UNIVERSITY

WAKAYAMA MEDICAL UNIVERSITY

ACTIVE

811-1, KIMIIDERA, Wakayama, Japanwww.wakayama-med.ac.jp/intro/index.htmlPrivateEstablished: 1945-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

219

13 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1945

Overview

Trial Phase Distribution

Phase

Trials

Share

Not Applicable

164

74.9%

Phase 3

14

6.4%

Unknown

13

5.9%

Phase 2

12

5.5%

Phase 1

10

4.6%

Phase 4

3

1.4%

Trial Status Distribution

Completed

138

63.0%

Not yet recruiting

13

5.9%

Recruiting

55

25.1%

Suspended

1

0.5%

Unknown

11

5.0%

Clinical Trials

Trials sponsored by this organization (219)

Study of protocolized lighter sedation during open abdomen management

Not yet recruiting

Feb 202480 participants

A single-center prospective observational study to investigate the actual situation of acute coronary syndrome and myocardial infarction with non-obstructive arteries.

Feb 2024500 participants

Serum trypsin as an early predictor of post-endoscopic retrograde pancreatography pancreatitis

Jan 2024147 participants

ationwide registry for needle tract seeding after endoscopic ultrasound-guided fine needle aspiration in pancreatic tumors

Nov 20232,900 participants

Stapler method for transection of the pancreatic parenchyma during pancreatoduodenectomy: Randomized control trial

Oct 2023136 participants

Study for the relationship between blood C-reactive protein (CRP) levels and blood tofacitinib levels in ulcerative colitis

May 202320 participants

Evaluation of endocrine disorders in IgG4 related disease: prospective cohort study.

Mar 202335 participants

Gastric Tube versus Whole Stomach Reconstruction after Esophagectomy for Esophageal Cancer: A Randomized Controlled Trial

Mar 2023130 participants

Page 1 of 28

Approvals

No approval data available

News

Gut Microbiome Metabolite HYA Shows Promise for Blood Sugar Management in Type 1 Diabetes

- A novel study reveals that HYA, a gut microbiome-derived metabolite, effectively reduces post-meal blood sugar spikes in type 1 diabetes model rats through multiple mechanisms. - Researchers from Wakayama Medical University, Hokkaido University, and Noster Inc. demonstrated that HYA enhances gut hormone secretion and inhibits glucose absorption without triggering inflammatory responses. - When combined with standard insulin therapy, HYA provided additional improvements in postprandial glucose control, suggesting potential as a complementary approach to traditional diabetes management.

On this page

Overview
Clinical Trials219
Approvals
News1

Back to Organizations